{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T02:42:12Z","timestamp":1777344132760,"version":"3.51.4"},"posted":{"date-parts":[[2025,4,4]]},"group-title":"Pediatrics","reference-count":46,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>IMPORTANCE<\/jats:title>\n                  <jats:p>Nirmatrelvir-ritonavir, an efficacious treatment for acute COVID-19, has yielded conflicting evidence regarding its effectiveness in preventing Long COVID among adults. The effectiveness of nirmatrelvir-ritonavir in adolescents in real-world settings is not well understood.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To evaluate the effectiveness of nirmatrelvir-ritonavir in adolescents aged 12 to 20 years given within the first five days of acute COVID-19 illness on illness severity during the acute (days 0 to 27) and post-acute phases (days 28 to 179).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>DESIGN, SETTING, AND PARTICIPANTS<\/jats:title>\n                  <jats:p>This target trial emulation used the electronic health records (EHR) data from twenty-nine medical institutions participating in the NIH\u2019s RECOVER consortium. We included data collected between April 1, 2022 and December 31, 2023, and included all patients with a SARS-CoV-2 infection who were not hospitalized on the day of entry. Those who were treated with oral nirmatrelvir-ritonavir within 5 days after the positive test (n=2,923) and those who did not received nirmatrelvir-ritonavir within 5 days after the positive test during the acute phase of SARS-CoV-2 infection (control group, n=31,947) were identified.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>EXPOSURES<\/jats:title>\n                  <jats:p>Treatment with nirmatrelvir-ritonavir based on prescription records.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>MAIN OUTCOMES AND MEASURES<\/jats:title>\n                  <jats:p>We used modified Poisson regression models for binary outcomes to examine the effects of nirmatrelvir-ritonavir on acute phase hospitalization, emergency department (ED) visits, and outpatient visits as well as progression to moderate or severe acute illness among individuals treated with nirmatrelvir-ritonavir compared to control counterparts. Additionally, we assessed the medication\u2019s associations with 16 conditions and symptoms during the acute phase of illness and its subsequent association with specific Long COVID diagnostic code U09.9 during the post-acute phase. We reported the absolute risks and estimated the relative risks (RRs), with adjustments made for demographic variables, clinical characteristics, and healthcare utilization, using propensity score matching.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The study cohort included 34,870 adolescents (median [Q1, Q3] age 16.0 [14.0, 18.0]); 46.0% male and 43.2% Non-Hispanic White. Among these patients, 2,923 were treated with nirmatrelvir-ritonavir within 5 days of cohort entry and 31,947 received no treatment. The absolute rates were 0.58% vs. 0.96% for hospitalization, 74.17% vs. 82.66% for outpatient visits, 1.81% vs. 2.28% for ED visits, 3.08% vs. 3.99% for moderate\/severe acute illness, and 0.21% vs. 0.20% for long COVID diagnosis in the treatment vs. control group. After propensity score matching, during acute-phase period, compared to the control group, nirmatrelvir-ritonavir was associated with reduced risk of any hospitalization (relative risk (RR) 0.48; 95% confidence interval (CI) 0.29-0.80), outpatient visit (RR 0.86; 95% CI 0.82-0.90), and moderate\/severe acute illness (RR 0.69; 95% CI 0.56-0.87). Additionally, nirmatrelvir-ritonavir was associated with reduced risk of 7 of 16 specified conditions in chest pain (RR 0.41; 95% CI 0.26-0.63), fatigue and malaise (RR 0.49; 95% CI 0.32-0.76), generalized pain (RR 0.65; 95% CI 0.45-0.95), headache (RR 0.60; 95% CI 0.44-0.83), mental health (RR 0.56; 95% CI 0.39-0.80), musculoskeletal (RR 0.63, 95% CI 0.43-0.94), and respiratory signs and symptoms (RR 0.61, 95% CI 0.52-0.71). No evidence was found to suggest that the treatment was associated with the risk of long COVID diagnosis U09.9 (RR 0.96, 95% CI 0.40-2.32).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>CONCLUSIONS AND RELEVANCE<\/jats:title>\n                  <jats:p>This study found that treatment with nirmatrelvir-ritonavir in adolescents within 5 days of SARS-CoV-2 infection, was associated with reduced risk of acute-phase COVID-19 illness and subsequent healthcare utilization. However, treatment was not associated with a lower risk of Long COVID diagnosis.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Question<\/jats:title>\n                    <jats:p>Does treatment with nirmatrelvir-ritonavir reduce the acute COVID-19 illness severity and the risk of developing Long COVID in adolescents aged 12 to 20 years?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In this target trial emulation study of 34,870 adolescents with SARS-CoV-2 infection who were not hospitalized on the cohort entry day, 2,923 who were treated with nirmatrelvir-ritonavir exhibited lower acute illness severity including reduced risk of 7 of 16 specified conditions and symptoms, as well as reduced risk of acute-phase hospitalization and outpatient visits, compared with 31,947 who received no treatment. The association with reduced risk of Long COVID was not observed in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Meaning<\/jats:title>\n                    <jats:p>In adolescents, nirmatrelvir-ritonavir appears to be effective at reducing the severity of acute COVID illness but was not associated with the risk of developing Long COVID.<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2025.04.02.25324861","type":"posted-content","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T08:49:00Z","timestamp":1744102140000},"source":"Crossref","is-referenced-by-count":4,"title":["Assessment of Nirmatrelvir-Ritonavir Effects on Acute and Post-Acute COVID-19 Illness in US Adolescents: Target Trial Emulation"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-8456","authenticated-orcid":false,"given":"Yishan","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-249X","authenticated-orcid":false,"given":"Bingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dazheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxi","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainu","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason G.","family":"Newland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon J.","family":"Herring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriy","family":"Bisyuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Liebovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2656-0263","authenticated-orcid":false,"given":"Benjamin D.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-8479","authenticated-orcid":false,"given":"Mollie R.","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Chrischilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay G.","family":"Cowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu Saleh Mohammad","family":"Mosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-068X","authenticated-orcid":false,"given":"Christopher B.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0835-0788","authenticated-orcid":false,"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025043020053552000_2025.04.02.25324861v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118542"},{"key":"2025043020053552000_2025.04.02.25324861v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309003"},{"key":"2025043020053552000_2025.04.02.25324861v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204919"},{"key":"2025043020053552000_2025.04.02.25324861v1.4","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients","volume":"76","year":"2023","journal-title":"Clin. Infect. Dis"},{"key":"2025043020053552000_2025.04.02.25324861v1.5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/M22-2141","article-title":"Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study","volume":"176","year":"2023","journal-title":"Ann. Intern. Med"},{"key":"2025043020053552000_2025.04.02.25324861v1.6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of Treatment With Nirmatrelvir and the Risk of Post\u2013COVID-19 Condition","volume":"183","year":"2023","journal-title":"JAMA Intern. Med"},{"key":"2025043020053552000_2025.04.02.25324861v1.7","doi-asserted-by":"crossref","unstructured":"Liu, T. H. , Wu, J. Y. , Huang, P. Y. , Tsai, Y. W. & Lai, C. C . The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19. J. Med. Virol. 95, (2023).","DOI":"10.1002\/jmv.28951"},{"key":"2025043020053552000_2025.04.02.25324861v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.12.021"},{"key":"2025043020053552000_2025.04.02.25324861v1.9","doi-asserted-by":"publisher","DOI":"10.1101\/2023.04.05.23288196"},{"key":"2025043020053552000_2025.04.02.25324861v1.10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S1473-3099(24)00217-2","article-title":"Association of nirmatrelvir\u2013ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study","volume":"24","year":"2024","journal-title":"Lancet Infect. Dis"},{"key":"2025043020053552000_2025.04.02.25324861v1.11","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-4536807\/V1"},{"key":"2025043020053552000_2025.04.02.25324861v1.12","doi-asserted-by":"crossref","unstructured":"Bajema, K. L. et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. medRxiv 11, (2022).","DOI":"10.1101\/2022.12.05.22283134"},{"key":"2025043020053552000_2025.04.02.25324861v1.13","doi-asserted-by":"crossref","unstructured":"Durstenfeld, M. S. et al. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J. Med. Virol. 96, (2024).","DOI":"10.1002\/jmv.29333"},{"key":"2025043020053552000_2025.04.02.25324861v1.14","first-page":"1","article-title":"Nirmatrelvir\/ritonavir and risk of long COVID symptoms: a retrospective cohort study","volume":"13","year":"2023","journal-title":"Sci. Reports 2023 131"},{"key":"2025043020053552000_2025.04.02.25324861v1.15","doi-asserted-by":"crossref","unstructured":"Chuang, M. H. et al. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J. Med. Virol. 95, (2023).","DOI":"10.1002\/jmv.28750"},{"key":"2025043020053552000_2025.04.02.25324861v1.16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamainternmed.2024.2007","article-title":"Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial","volume":"184","year":"2024","journal-title":"JAMA Intern. Med"},{"key":"2025043020053552000_2025.04.02.25324861v1.17","unstructured":"Management Strategies in Children and Adolescents with Mild to Moderate COVID-19. https:\/\/www.aap.org\/en\/pages\/2019-novel-coronavirus-covid-19-infections\/clinical-guidance\/outpatient-covid-19-management-strategies-in-children-and-adolescents\/."},{"key":"2025043020053552000_2025.04.02.25324861v1.18","unstructured":"FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID. https:\/\/www.fda.gov\/media\/155050\/download#:~:text=U.S. Food and Drug Administration,of pediatric patients 12 years."},{"key":"2025043020053552000_2025.04.02.25324861v1.19","unstructured":"CDC. Types of COVID-19 Treatment. https:\/\/www.cdc.gov\/covid\/treatment\/index.html."},{"key":"2025043020053552000_2025.04.02.25324861v1.20","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/hpeds.2023-007132","article-title":"Pediatric Nirmatrelvir\/Ritonavir Prescribing Patterns During the COVID-19 Pandemic","volume":"14","year":"2024","journal-title":"Hosp. Pediatr"},{"key":"2025043020053552000_2025.04.02.25324861v1.21","first-page":"321","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults","volume":"602","year":"2021","journal-title":"Nat. 2021 6027896"},{"key":"2025043020053552000_2025.04.02.25324861v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01202-8"},{"key":"2025043020053552000_2025.04.02.25324861v1.23","unstructured":"ClinicalTrials.gov . EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)\/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease. https:\/\/clinicaltrials.gov\/study\/NCT05261139."},{"key":"2025043020053552000_2025.04.02.25324861v1.24","doi-asserted-by":"crossref","unstructured":"Dalton, A. F. et al. 1937. Use of Paxlovid for Treatment of Acute COVID-19 and Occurrence of Post-COVID Conditions among Children and Adults at High-Risk for Severe COVID-19, April 1 - December 31, 2022. Open Forum Infect. Dis. 10, (2023).","DOI":"10.1093\/ofid\/ofad500.2468"},{"key":"2025043020053552000_2025.04.02.25324861v1.25","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41467-024-49235-8","article-title":"Effectiveness of nirmatrelvir\/ritonavir in children and adolescents aged 12\u201317 years following SARS-CoV-2 Omicron infection: A target trial emulation","volume":"15","year":"2024","journal-title":"Nat. Commun"},{"key":"2025043020053552000_2025.04.02.25324861v1.26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-2151"},{"key":"2025043020053552000_2025.04.02.25324861v1.27","unstructured":"Infectious Diseases Society of America. Management of Drug Interactions With Nirmatrelvir\/Ritonavir (Paxlovid\u00ae): Resource for Clinicians. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid\/ (2022)."},{"key":"2025043020053552000_2025.04.02.25324861v1.28","doi-asserted-by":"crossref","first-page":"2023064446","DOI":"10.1542\/peds.2023-064446","article-title":"Vaccine Effectiveness Against Long COVID in Children","volume":"153","year":"2024","journal-title":"Pediatrics"},{"key":"2025043020053552000_2025.04.02.25324861v1.29","doi-asserted-by":"crossref","unstructured":"Skelly, A. C. , Dettori, J. R. & Brodt, E. D . Assessing bias: the importance of considering confounding. Evid. Based. Spine. Care. J. 3, 9 (2012).","DOI":"10.1055\/s-0031-1298595"},{"key":"2025043020053552000_2025.04.02.25324861v1.30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/M23-1754","article-title":"Real-world effectiveness of BNT162b2 against infection and severe diseases in children and adolescents","volume":"177","year":"2024","journal-title":"Ann. Intern. Med"},{"key":"2025043020053552000_2025.04.02.25324861v1.31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.acap.2018.02.010","article-title":"Development and Validation of the Pediatric Medical Complexity Algorithm (PMCA) Version 3.0","volume":"18","year":"2018","journal-title":"Acad. Pediatr"},{"key":"2025043020053552000_2025.04.02.25324861v1.32","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamapediatrics.2022.2800","article-title":"Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents","volume":"176","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2025043020053552000_2025.04.02.25324861v1.33","doi-asserted-by":"publisher","DOI":"10.1201\/B16343\/EPIDEMIOLOGY-MARK-WOODWARD\/ACCESSIBILITY-INFORMATION"},{"key":"2025043020053552000_2025.04.02.25324861v1.34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.37737\/ace.22005","article-title":"Introduction to Matching in Case-Control and Cohort Studies","volume":"4","year":"2022","journal-title":"Ann. Clin. Epidemiol"},{"key":"2025043020053552000_2025.04.02.25324861v1.35","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2025043020053552000_2025.04.02.25324861v1.36","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"key":"2025043020053552000_2025.04.02.25324861v1.37","doi-asserted-by":"crossref","unstructured":"Wu, Q. , et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. EClinicalMedicine 79, (2025).","DOI":"10.1016\/j.eclinm.2024.102962"},{"key":"2025043020053552000_2025.04.02.25324861v1.38","doi-asserted-by":"crossref","first-page":"e2441970","DOI":"10.1001\/jamanetworkopen.2024.41970","article-title":"Body mass index and postacute sequelae of SARS-CoV-2 infection in children and young adults","volume":"7","year":"2024","journal-title":"JAMA Netw. open"},{"key":"2025043020053552000_2025.04.02.25324861v1.39","unstructured":"Zhang, B. , et al. Post-Acute Cardiovascular Outcomes of COVID-19 in Children and Adolescents: An EHR Cohort Study from the RECOVER Project. medRxiv (2024)."},{"key":"2025043020053552000_2025.04.02.25324861v1.40","doi-asserted-by":"crossref","first-page":"e2021055765","DOI":"10.1542\/peds.2021-055765","article-title":"Severity of acute COVID-19 in children< 18 years old March 2020 to December 2021","volume":"149","year":"2022","journal-title":"Pediatrics"},{"key":"2025043020053552000_2025.04.02.25324861v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32317-7"},{"key":"2025043020053552000_2025.04.02.25324861v1.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1708282114"},{"key":"2025043020053552000_2025.04.02.25324861v1.43","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5925"},{"key":"2025043020053552000_2025.04.02.25324861v1.44","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1093\/cid\/ciaa169","article-title":"Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections","volume":"71","year":"2020","journal-title":"Clin. Infect. Dis"},{"key":"2025043020053552000_2025.04.02.25324861v1.45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/pds.4680","article-title":"Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrence","volume":"28","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"2025043020053552000_2025.04.02.25324861v1.46","first-page":"1764","volume":"2016","year":"2017","journal-title":"An empirical study for impacts of measurement errors on EHR based association studies. in AMIA Annual Symposium Proceedings"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.04.02.25324861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:33:05Z","timestamp":1768509185000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.04.02.25324861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1101\/2025.04.02.25324861","relation":{},"subject":[],"published":{"date-parts":[[2025,4,4]]},"subtype":"preprint"}}